Inhibition of poly(ADP-ribose) polymerase in cancer

Current Opinion in Pharmacology

Volumn 6, Issue 4, 2006, Pages 364-368

  Plummer, Elizabeth Ruth ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; AG 014699; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BENZIMIDAZOLE 4 CARBOXAMIDE; BENZIMIDAZOLE DERIVATIVE; BLEOMYCIN; CAMPTOTHECIN; CARBAZOLE DERIVATIVE; CEP 6800; CISPLATIN; CYTOTOXIC AGENT; DEMETHYL SULFATE; DNA; ETOPOSIDE; GEMCITABINE; GPI 15427; INO 1001; IRINOTECAN; KU 00559436; NEW DRUG; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NOLATREXED; NU 1085; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG;

BONE MARROW TOXICITY; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CYTOTOXICITY; DNA ALKYLATION; DNA REPAIR; DRUG INDICATION; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 33745876586     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.02.004     Document Type: Review

References (43)

1. Madhusudan S., and Middleton M.R. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 31 (2005) 603-617. Recent comprehensive review on DNA repair proteins and early drugs in clinic.
2. Bernstein C., Bernstein H., Payne C.M., and Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 511 (2002) 145-178
3. Christmann M., Tomicic M.T., Roos W.P., and Kaina B. Mechanisms of human DNA repair: an update. Toxicology 193 (2003) 3-34
4. Hoeijmakers J.H. Genone maintenance mechanisms for preventing cancer. Nature 411 (2001) 366-374
5. Ames B.N., and Gold L.S. Endogenous mutagens and the causes of aging and cancer. Mutat Res 250 (1991) 3-16
6. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat Med 10 (2004) 789-799
7. Fink D., Aebi S., and Howell S. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4 (1998) 1-6
8. Soejima H., Zhao W., and Mukai T. Epigenetic silencing of the MGMT gene in cancer. Biochem Cell Biol 83 (2005) 429-437
9. Park Y., and Gerson S.L. DNA repair defects in stem cell function and aging. Annu Rev Med 56 (2005) 495-508
10. Chambon P., Weil J., and Mandel P. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid sythesizing nuclear enzyme. Biochem Biophys Res Commun 11 (1963) 39
11. de Murcia G., and Menissier de Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 19 (1994) 172-176
12. Davidovic L., Vodenicharov M., Affar E.B., and Poirier G.G. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. Exp Cell Res 268 (2001) 7-13
13. Curtin N.J. PARP inhibitors for cancer therapy. Expert Rev Mol Med 7 (2005) 1-20. Excellent recent review of preclinical work leading to early clinical trials of PARP inhibitors.
14. Purnell M.R., and Whish W.J.D. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem J 185 (1980) 775-777
15. Griffin R.J., Pemberton L.C., Rhodes D., Bleasdale C., Bowman K., Calvert A.H., Curtin N.J., Durkacz B.W., Newell D.R., Porteous J.K., et al. Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP). Anticancer Drug Des 10 (1995) 507-514
16. Southan G., and Szabo C. Poly(ADP-ribose) ploymerase inhibitors. Curr Med Chem 10 (2003) 321-340
17. n participates in DNA excision repair. Nature 283 (1980) 593-596
18. Bowman K.J., White A., Golding B.T., Griffin R.J., and Curtin N.J. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 78 (1998) 1269-1277
19. Boulton S., Pemberton L.C., Porteous J.K., Curtin N.J., Griffin R.J., Golding B.T., and Durkacz B.W. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 72 (1995) 849-856
20. Bowman K.J., Newell D.R., Calvert A.H., and Curtin N.J. Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 84 (2001) 106-112
21. Delaney C.A., Wang L.Z., Kyle S., White A.W., Calvert A.H., Curtin N.J., Durkacz B.W., Hostomsky Z., and Newell D.R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 6 (2000) 2860-2867
22. Miknyoczki S.J., Jones-Bolin S., Pritchard S., Hunter K., Zhao H., Wan W., Ator M., Bihovsky R., Hudkins R., Chatterjee S., et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2 (2003) 371-382
23. Tentori L., Leonetti C., Scarsella M., D'Amati G., Vergati M., Portarena I., Xu W., Kalish V., Zupi G., Zhang J., and Graziani G. Systemic administration of GPI, 15427 a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 9 (2003) 5370-5379
24. Cheng C.L., Johnson S.P., Keir S.T., Quinn J.A., Ali-Osman F., Szabo C., Li H., Salzman A.L., Dolan M.E., Modrich P., et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 4 (2005) 1364-1368
25. Calabrese C.R., Batey M.A., Thomas H.D., Durkacz B.W., Wang L.Z., Kyle S., Skalitzky D., Li J., Zhang C., Boritzki T., et al. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res 9 (2003) 2711-2718
26. Calabrese C.R., Almassy R., Barton S., Batey M.A., Calvert A.H., Canan-Koch S., Durkacz B.W., Hostomsky Z., Kumpf R.A., Kyle S., et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96 (2004) 56-67. Preclinical data detailing the early work with the class of PARP inhibitors first taken into cancer therapy trials.
27. Tentori L., and Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52 (2005) 25-33. Recent review of all preclinical data demonstrating chemopotentiation with a range of cytotoxics.
28. Tentori L., Leonetti C., Scarsella M., d'Amati G., Portarena I., Zupi G., Bonmassar E., and Graziani G. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 99 (2002) 2241-2244
29. Tentori L., Turriziani M., Franco D., Serafino A., Levati L., Roy R., Bonmassar E., and Graziani G. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia 13 (1999) 901-909
30. Tentori L., Portarena I., Vernole P., De Fabritiis P., Madaio R., Balduzzi A., Roy R., Bonmassar E., and Graziani G. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Cancer Chemother Pharmacol 47 (2001) 361-369
31. Plummer R, Middleton M, Wilson R, Jones C, Evans J, Robson L, Steinfeldt H, Kaufman R, Reich S, Calvert AH. First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. ASCO Meeting Abstracts 2005:3065.
32. Beneke S., Diefenbach J., and Burkle A. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int J Cancer 111 (2004) 813-818
33. Veuger S.J., Curtin N.J., Richardson C.J., Smith G.C., and Durkacz B.W. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 63 (2003) 6008-6015
34. Barnes D.E., and Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 38 (2004) 445-476
35. Masutani M., Nozaki T., Nakamoto K., Nakagama H., Suzuki H., Kusuoka O., Tsutsumi M., and Sugimura T. The response of Parp knockout mice against DNA damaging agents. Mutat Res 462 (2000) 159-166
36. ••]).
37. ••], showing hypersensitivity of BRCA-2 homozygous cells in vivo, in vitro and using short interfering RNA.
38. Ashworth A. Oh what a tangled web it weaves: BRCA1 and DNA decatenation. Cancer Cell 8 (2005) 95-97
39. Haince J.F., Rouleau M., Hendzel M.J., Masson J.Y., and Poirier G.G. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol Med 11 (2005) 456-463
40. Szabo C. Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions. Curr Vasc Pharmacol 3 (2005) 301-303. Recent review of cardiovascular indications by a leading researcher in field.
41. Cuzzocrea S: Shock. inflammation and PARP. Pharmacol Res 52 (2005) 72-82
42. Graziani G., and Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 52 (2005) 109-118
43. Jagtap P., and Szabo C. Poly(ADP-Ribose)polymerase and the therapeautic effects of its inhibitors. Nat Rev Drug Discov 4 (2005) 421-440